CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: Induction of clinical remission and cellular immunity

Transplantation

Volumn 96, Issue 3, 2013, Pages

  Theurich, Sebastian ^a   Wennhold, Kerstin ^a   Wedemeyer, Inga ^a   Rothe, Achim ^a   Hübel, Kai ^a   Shimabukuro Vornhagen, Alexander ^a   Holtick, Udo ^a   Hallek, Michael ^a   Scheid, Christof ^a   Von Bergwelt Baildon, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; BUSULFAN; CD30 ANTIGEN; CYCLOSPORIN; FLUDARABINE; METHOTREXATE;

AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; CASE REPORT; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE CONTROL; DONOR LYMPHOCYTE INFUSION; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; POLYNEUROPATHY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REMISSION; T CELL LYMPHOMA; THROMBOCYTOPENIA;

AGED; ANTIGENS, CD30; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOCONJUGATES; LYMPHOCYTE TRANSFUSION; LYMPHOMA, T-CELL; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84881588241     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829a9258     Document Type: Letter

References (10)

1. Jagadeesh D,Woda BA, Draper J, et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122.
2. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196.
3. Caillard S, Porcher R, Provot F, et al. Posttransplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol 2013; 31: 1302.
4. Tiede C, Maecker-Kolhoff B, Klein C, et al. Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. Transplantation 2013; 95: 479.
5. Perez K, Castillo J, Dezube BJet al.Human immunodeficiency virus-associated anaplastic large cell lymphoma. Leuk Lymphoma 2010; 51: 430.
6. Balachandran I, Walker JW Jr, Broman J. Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review. Diagn Cytopathol 2010; 38:213.
7. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120: 560.
8. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812.
9. Galand C, Donnou S, Crozet L, et al. Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma. PLoS One 2011; 6: e24622.
10. Kesselring R, Thiel A, Pries R, et al. The number of CD161 positive Th17 cells are decreased in head and neck cancer patients. Cell Immunol 2011; 269: 74.